Catch up on the top radiology content of the past week.
|Articles|February 2, 2000
NASI, Theseus announce technical milestone
North American Scientific and Theseus Imaging reported that clinical trials of Theseus’ Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit
Advertisement
North American Scientific and Theseus Imaging reported that clinical trials of Theseus Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit has been used in nuclear medicine procedures in more than 3500 hospitals across the U.S.
Patients who undergo heart transplants can have up to 15 catheterization procedures during the first year after the surgery to evaluate the immunosuppression medications effectiveness, according to the two companies. Theseus hopes Apomate will contribute equivalent information noninvasively by imaging the functional changes that occur when the body rejects an organ.
North American and Theseus signed a merger agreement in October, which is subject to final due diligence, according to Chatsworth, CA-based NASI. Theseus develops radiopharmaceutical products for in vivo medical imaging.
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging's Weekly Scan: September 27 — October 3
2
The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 1
3
Raising Questions on the Prognostic Value of Fractional Flow Reserve from CCTA
4
FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection
5